{"filing":{"accession_number":"0001213900-26-095981","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"ea0304199-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026095981/ea0304199-6k_clearmind.htm"},"events":[{"id":30800,"run_id":28241,"accession_number":"0001213900-26-095981","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a material clinical development milestone: initiation of Phase IIa of Clearmind's Phase I/IIa clinical trial for CMND-100 in alcohol use disorder treatment, with six patients enrolled across two Israeli medical centers. The announcement emphasizes successful completion of Part A safety data and a positive Data and Safety Monitoring Board recommendation to advance to multiple-dose phases. For a clinical-stage biopharmaceutical company, progression to Phase IIa with patient enrollment represents a significant operational and strategic milestone that would affect a reasonable investor's assessment of the company's development pipeline and near-term prospects.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":[{"id":33513,"accession_number":"0001213900-26-095981","item_number":"EX-99.1","item_title":"ea030419902ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a material clinical development milestone: initiation of Phase IIa of Clearmind's Phase I/IIa clinical trial for CMND-100 in alcohol use disorder treatment, with six patients enrolled across two Israeli medical centers. The announcement emphasizes successful completion of Part A safety data and a positive Data and Safety Monitoring Board recommendation to advance to multiple-dose phases. For a clinical-stage biopharmaceutical company, progression to Phase IIa with patient enrollment represents a significant operational and strategic milestone that would affect a reasonable investor's assessment of the company's development pipeline and near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T12:02:55.271361+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33513,"accession_number":"0001213900-26-095981","item_number":"EX-99.1","item_title":"ea030419902ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a material clinical development milestone: initiation of Phase IIa of Clearmind's Phase I/IIa clinical trial for CMND-100 in alcohol use disorder treatment, with six patients enrolled across two Israeli medical centers. The announcement emphasizes successful completion of Part A safety data and a positive Data and Safety Monitoring Board recommendation to advance to multiple-dose phases. For a clinical-stage biopharmaceutical company, progression to Phase IIa with patient enrollment represents a significant operational and strategic milestone that would affect a reasonable investor's assessment of the company's development pipeline and near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T12:02:55.271361+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-09-01"}]}